Outset Medical (OM) Expected to Post Earnings on Wednesday

Outset Medical (NASDAQ:OM) will likely be posting its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to post earnings of ($0.64) per share and revenue of $31.40 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Outset Medical (NASDAQ:OM) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). The firm had revenue of $31.64 million for the quarter, compared to analyst estimates of $28.97 million. Outset Medical had a negative return on equity of 61.67% and a negative net margin of 63.06%. On average, analysts expect Outset Medical to post ($3.81) EPS for the current fiscal year and ($3.01) EPS for the next fiscal year.

Outset Medical Stock Performance

OM stock traded up $0.11 during midday trading on Tuesday, hitting $4.13. The stock had a trading volume of 7,162 shares, compared to its average volume of 340,293. Outset Medical has a 52 week low of $2.84 and a 52 week high of $12.97. The company has a current ratio of 5.19, a quick ratio of 4.11 and a debt-to-equity ratio of 1.03. The stock has a 50-day simple moving average of $3.72 and a 200 day simple moving average of $4.16. The firm has a market capitalization of $77.64 million, a price-to-earnings ratio of -1.01 and a beta of 1.99.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Weiss Ratings cut shares of Outset Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 21st. Wall Street Zen raised shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $10.00.

Outset Medical Company Profile

Outset Medical, Inc is a medical technology company that develops products for hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys are no longer able to do so adequately. The company’s primary product is the Tablo Hemodialysis System, an integrated dialysis platform designed to simplify treatment for healthcare providers and support broader use of dialysis in hospitals, outpatient facilities and the home.

The Tablo system combines dialysis delivery, water purification and dialysate production in a single device and uses a touchscreen interface intended to guide users through treatment setup and operation.